WhiteBoard style discussion on a new paper in pre-print that uses lenzilumab, a monoclonal antibody inhibiting GM-CSF (cytokine) to treat moderate to severe COVID-19. This medication has been used successfully for the treatment of cytokine storms that can result after CART Therapy (a therapy for cancer that hyper-stimulates T cells to attack the cancer). They treated 12 patients with moderate to severe COVID-19. We will discuss what lenzilumab is and it's use to treat cytokine storms after CART therapy. We will then dive into this study checking out safety profiles and efficacy. Check out the video for more details and the results!
We have just recently debuted a Patreon page with exclusive perks, WhiteBoard Doctor merchandise, and more! Come check it out and consider becoming a WBDR Patreon!
https://www.patreon.com/WBDR
Link to study:
https://www.medrxiv.org/content/10.1101/2020.06.08.20125369v2.full.pdf
There will be a running series of videos using the most up to date information on COVID-19, but this is an evolving field and new videos may come out that contradict that previous information. That is okay and is the nature of a fast paced and evolving clinical scenario. Stick with us as we work to unveil the intricacies of COVID-19, it's clinical significance, and the societal implications. ***This is strictly educational and not to be mistaken as clinical recommendations, please verify all information with accepted guidelines and practice patterns.***
DISCLAIMER
THIS VIDEO DOES NOT PROVIDE MEDICAL ADVICE. The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read, watched, or listened to on this video, or any other videos, reports, texts tweets or other sources.
19:13
20:22
18:31
19:25
